Filing Analysis
Nordicus Partners Corp entered into two consulting agreements on November 27, 2024, to secure investor relations services. These include a cash-based agreement with Harbor Access LLC and an equity-based agreement with ESG Advisor Group, L.L.C.
🚩 Red Flags
- Equity-based compensation to consultants (ESG Advisor Group) can lead to significant dilution for existing shareholders.
- Performance-based milestones for share issuance (volume and price targets) may create misaligned incentives between the company and the consultant regarding stock price volatility.
📋 Key Facts
- Entered into a Consulting Agreement with Harbor Access LLC for $8,000 per month through November 30, 2025.
- Entered into a Professional Relations and Consulting Agreement with ESG Advisor Group, L.L.C. involving the issuance of 61,500 restricted shares of common stock.
- ESG shares vest in tranches: 15,300 shares after 45 days, followed by up to 11 monthly tranches of 4,200 shares.
- ESG is eligible for additional share bonuses based on volume and trading price milestones.
- The equity issuance was conducted via exemptions under Section 4(a)(2), Rule 506(b), or Rule 701.
Nordicus Partners Corp completed the acquisition of Orocidin A/S, a Danish stock corporation, making it a 100% owned subsidiary. The transaction was executed via a stock-for-stock swap where the company issued 200,000 restricted shares to acquire 5.34% of Orocidin's outstanding capital stock.
🚩 Red Flags
- The acquisition was completed via the issuance of unregistered, restricted common stock.
- Transaction involves an exchange of equity for a minority stake that results in 100% ownership, suggesting potentially complex valuation or restructuring mechanics.
📋 Key Facts
- Acquisition date: November 12, 2024.
- Target: Orocidin A/S (Danish stock corporation).
- Consideration: Issuance of 200,000 restricted shares of Nordicus Partners Corp common stock.
- Assets acquired: 29,663 shares of Orocidin capital stock (representing 5.34% of Orocidin's outstanding shares).
- Resulting ownership: Orocidin is now a 100% owned subsidiary of Nordicus Partners Corp.
Nordicus Partners Corp acquired 100% of Bio-Convert ApS, a Danish stock corporation, in an all-stock transaction. The company issued 12,000,000 restricted shares of its common stock to the sellers of Bio-Convert.
🚩 Red Flags
- Significant dilution potential due to the issuance of 12,000,000 new restricted shares.
- Unregistered securities: The shares issued to the sellers have not been registered under the Securities Act and are subject to legends/transfer restrictions.
📋 Key Facts
- Acquisition date: November 12, 2024.
- Target: Bio-Convert ApS (Danish stock corporation).
- Assets acquired: 595,400 shares representing 100% of Bio-Convert's outstanding capital stock.
- Consideration: Issuance of 12,000,000 restricted shares of Nordicus Partners Corp common stock.
- The shares issued were not registered under the Securities Act and are subject to transfer restrictions.
Nordicus Partners Corporation announced the resignation of Christian Hill-Madsen from its Board of Directors, effective June 3, 2024. Peter Severin has been appointed as his replacement and will serve as Chairman of the Board.
🚩 Red Flags
- Potential conflict of interest: The departing director remains Chairman of a major subsidiary (Orocidin A/S) that was recently acquired via a share exchange with the parent company.
📋 Key Facts
- Christian Hill-Madsen resigned from the Board of Directors on June 3, 2024.
- Peter Severin appointed to replace Hill-Madsen and serve as Chairman of the Board.
- The Board approved new director compensation: $20,000 per annum for the Chairman and $10,000 per annum for other Directors.
- Hill-Madsen will remain Chairman of Orocidin A/S, a company in which Nordicus recently acquired a 95% stake.
Nordicus Partners Corp completed a significant acquisition of 95.0% of Orocidin A/S, a Danish stock corporation, on May 13, 2024. The transaction was funded through the issuance of 38,000,000 restricted shares of Nordicus common stock to the sellers.
🚩 Red Flags
- Massive dilution: The issuance of 38,000,000 restricted shares represents a significant expansion of the share count which may heavily dilute existing shareholders.
- Unregistered securities: The 38 million shares issued are 'restricted' and not registered under the Securities Act, meaning they cannot be easily liquidated by the sellers in the public market immediately.
📋 Key Facts
- Acquired 525,597 shares of Orocidin A/S, representing 95.0% of its outstanding capital stock.
- Consideration paid: Issuance of 38,000,000 restricted shares of Nordicus Partners Corp common stock.
- Transaction consummated on May 13, 2024.
- The issuance was made to 'Sellers' who are described as shareholders of Orocidin A/S.
- The new shares were issued under exemptions from registration (Section 4(a)(2), Rule 506(b), or Regulation S).